Lantheus Holdings (LNTH) Non Operating Investment Income (2024 - 2026)
Lantheus Holdings (LNTH) posted quarterly Non Operating Investment Income of $14.9 million for Q1 2026, up 200.29% year-over-year from $5.0 million in Q1 2025, and up 257.09% quarter-over-quarter from -$9.5 million in Q4 2025.
Lantheus Holdings (LNTH) Non Operating Investment Income (2024 - 2026) Analysis & Trends
Lantheus Holdings (LNTH) has reported Non Operating Investment Income for 3 consecutive years, with $14.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non Operating Investment Income rose 200.29% year-over-year to $14.9 million; the TTM figure through Mar 2026 stood at $21.2 million (up 117.75% YoY), while the FY2025 annual figure was -$8.6 million, up 80.22% from the prior year.
- Non Operating Investment Income advanced to $14.9 million in Q1 2026 per LNTH's latest filing, from -$9.5 million in the prior quarter.
- Across five years, Non Operating Investment Income topped out at $60.7 million in Q1 2024 and bottomed at -$119.1 million in Q4 2024.
- Historically, Non Operating Investment Income has averaged -$4.1 million across 3 years, with a median of $1.2 million in 2025.
- Annual changes were most pronounced in 2025 — Non Operating Investment Income tumbled 124.48% — and 2026, when it surged 200.29%.
- Lantheus Holdings' Non Operating Investment Income stood at -$119.1 million in 2024, then soared by 92.03% to -$9.5 million in 2025, then jumped by 257.09% to $14.9 million in 2026.
- Business Quant data shows LNTH's Non Operating Investment Income at $14.9 million in Q1 2026, -$9.5 million in Q4 2025, and $1.2 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | - |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Lantheus Holdings | 6.52 Bn | 5.93 Bn | 241.86 Mn | -9.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -9.54 Mn |
| Jun 30, 2026 | -9.54 Mn |
| Mar 31, 2026 | 14.91 Mn |
| Mar 31, 2026 | 14.91 Mn |
| Dec 31, 2025 | -9.49 Mn |
| Dec 31, 2025 | -9.49 Mn |
| Sep 30, 2025 | 1.16 Mn |
| Sep 30, 2025 | 1.16 Mn |
| Jun 30, 2025 | 14.57 Mn |
| Jun 30, 2025 | 14.57 Mn |
| Mar 31, 2025 | -14.86 Mn |
| Mar 31, 2025 | -14.86 Mn |
| Dec 31, 2024 | -119.06 Mn |
| Dec 31, 2024 | -119.06 Mn |
| Sep 30, 2024 | 37.33 Mn |
| Sep 30, 2024 | 37.33 Mn |
| Jun 30, 2024 | -22.54 Mn |
| Jun 30, 2024 | -22.54 Mn |
| Mar 31, 2024 | 60.70 Mn |
| Mar 31, 2024 | 60.70 Mn |